Affinity maturation is the process of improving antibody affinity and binding interactions to target antigens. This is done naturally in vivo by multiple rounds of somatic hypermutation and clonal selection in the germinal center, but affinity maturation can also be processed in the lab in vitro through repeated mutagenesis and selection. This is particularly useful for therapeutic applications, where desired antibody activity is crucial.
In Vivo Affinity Maturation
In vivo affinity maturation occurs in the germinal centers of lymphoid tissues, where B cells undergo several rounds of somatic hypermutation and clonal selection to improve their affinity for antigens. This process is initiated when the immune system repeatedly encounters the same pathogen, triggering B cells to continuously evolve and produce antibodies with greater affinity, avidity, and anti-pathogen activity over time.
This is because of somatic hypermutation in variable CDRs (complementarity-determining regions) of immunoglobulin genes in B cells. These variable regions, particularly the complementarity-determining regions (CDRs), are responsible for antigen binding. Through random mutations in the CDRs, a diverse pool of antibodies is generated, each with slightly different binding affinities.
Once somatic hypermutation has produced a variety of B cells with mutated antibodies, clonal selection takes place. In this phase, follicular dendritic cells in the germinal centers present antigens to the B cells, and only those with the highest affinity for the antigen are selected for survival. These high-affinity B cells then interact with follicular helper T cells, further promoting their maturation into memory B cells or plasma cells, which produce large quantities of high-affinity antibodies.1
Related: Affinity Maturation
In Vitro Affinity Maturation
While the immune system has evolved mechanisms for optimizing antibody affinity, these processes can be replicated and even improved upon in a controlled laboratory environment. In vitro affinity maturation offers a pathway to optimize antibodies, antibody fragments, or other peptides by diversifying the antibody base sequence and isolating higher-affinity binders.
The in vitro process involves diversifying the antibody’s gene sequence through mutagenesis, followed by rounds of selection to isolate those variants that exhibit enhanced affinity for the target antigen. This method is particularly useful when dealing with non-immunogenic antigens or when there is a need to develop antibodies with specificity beyond what the immune system can naturally achieve.
While different methods exist, site saturation mutagenesis is commonly used, in addition to high-throughput mammalian cell expression, ELISA (enzyme-linked immunosorbent assay) and sequencing to identify hot spots, and combinatorial mutation design and characterization.
Advances in Technology
As biotechnology continues to advance, new technologies are emerging to further improve the affinity maturation process. Artificial intelligence (AI) and machine learning algorithms are increasingly being used to predict beneficial mutations and streamline the selection process. By analyzing large datasets of antibody-antigen interactions, AI tools can identify key structural features that contribute to high affinity, guiding researchers in designing more effective antibodies.
In addition, advances in next-generation sequencing (NGS) allow researchers to rapidly sequence large antibody libraries, providing deeper insights into the relationship between antibody structure and function. This high-resolution data can be used to refine affinity maturation strategies and accelerate the discovery of new therapeutic antibodies.
Doria-Rose, N. A., & Joyce, M. G. (2015). Strategies to guide the antibody affinity maturation process. Current Opinion in Virology, 11, 137. https://doi.org/10.1016/j.coviro.2015.04.002
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
